健民集团(600976.SH)：氨溴特罗口服溶液获批上市

Core Viewpoint - The company, Jianmin Group, has received approval from the National Medical Products Administration for its drug, Ambroxol and Clenbuterol Oral Solution, which is expected to enhance its product line and core competitiveness, positively impacting future development [1] Group 1: Product Approval - The drug Ambroxol and Clenbuterol Oral Solution has been granted the approval number CYHS2201805 and the registration number H20256088 [1] - This formulation consists of two active ingredients: Ambroxol Hydrochloride, a mucolytic agent that reduces the viscosity of phlegm, and Clenbuterol Hydrochloride, a selective β-agonist that relaxes bronchial smooth muscle and promotes phlegm expulsion [1] Group 2: Market Potential - The combination of these two components provides a synergistic effect for cough relief and phlegm expulsion, indicating a mature clinical application and a large market capacity [1] - The approval of this generic chemical drug will further enrich the company's product line, enhancing its core competitiveness [1]